| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 2022 |
Subbuvel M, Kavan P. Preparation and characterization of polylactic acid/fenugreek essential oil/curcumin composite films for food packaging applications. International Journal of Biological Macromolecules. 194: 470-483. PMID 34800525 DOI: 10.1016/j.ijbiomac.2021.11.090 |
0.01 |
|
| 2021 |
Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, Shivakumar S, Suryanarayan D, Tagalakis V, Wu C, Lee AYY. Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. Current Oncology (Toronto, Ont.). 28: 5434-5451. PMID 34940092 DOI: 10.3390/curroncol28060453 |
0.01 |
|
| 2021 |
Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C, Srivastava A, Hébert S, Samson B, Lespérance B, Ko YJ, Dalfen R, St-Hilaire E, Sideris L, Couture F, ... ... Kavan P, et al. Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. Clinical and Translational Medicine. 11: e401. PMID 33931971 DOI: 10.1002/ctm2.401 |
0.01 |
|
| 2021 |
Elkrief A, Redstone G, Petruccelli L, Ali A, Thomas D, Fernandez M, Rousseau C, Aleynikova O, Anderson D, Ghitulescu G, Vasilevsky CA, Dalfen R, Langleben A, Liberman S, Kavan P, et al. Reasons for delay in timely administration of adjuvant chemotherapy for patients with stage III colon cancer: a multicentre cohort study from the McGill University Department of Oncology. Bmj Open Quality. 10. PMID 33685857 DOI: 10.1136/bmjoq-2020-000934 |
0.01 |
|
| 2021 |
Meyers BM, Vogel A, Marotta P, Kavan P, Kamboj L, Pan J, Geadah M, Trueman D, Sabapathy S. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective. Canadian Journal of Gastroenterology & Hepatology. 2021: 8811018. PMID 33681090 DOI: 10.1155/2021/8811018 |
0.01 |
|
| 2020 |
Khorana AA, Cohen AT, Carrier M, Meyer G, Pabinger I, Kavan P, Wells PS. Prevention of venous thromboembolism in ambulatory patients with cancer. Esmo Open. 5. PMID 33229505 DOI: 10.1136/esmoopen-2020-000948 |
0.01 |
|
| 2020 |
Garant A, Kavan P, Martin AG, Azoulay L, Vendrely V, Lavoie C, Vasilevsky CA, Boutros M, Faria J, Nghia Nguyen T, Ferland E, Des Groseilliers S, Cloutier AS, Diec H, Drolet S, et al. Optimizing Treatment Sequencing of Chemotherapy for Patients with Rectal Cancer: the KIR Randomized Phase II Trial. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 33220397 DOI: 10.1016/j.radonc.2020.11.008 |
0.01 |
|
| 2020 |
Cheung WY, Kavan P, Dolley A. Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. Current Oncology (Toronto, Ont.). 27: e451-e458. PMID 33173384 DOI: 10.3747/co.27.6533 |
0.01 |
|
| 2020 |
Evaristo G, Fiset PO, Camilleri-Broët S, Vanounou T, Kavan P, Spatz A, Wang H. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma. The American Journal of Surgical Pathology. 44: 1290-1292. PMID 32452871 DOI: 10.1097/PAS.0000000000001483 |
0.01 |
|
| 2020 |
Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, et al. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. Jama Oncology. PMID 32379280 DOI: 10.1001/jamaoncol.2020.0910 |
0.01 |
|
| 2019 |
Kennecke H, Berry S, Maroun J, Kavan P, Aucoin N, Couture F, Poulin-Costello M, Gillesby B. A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada. Current Oncology (Toronto, Ont.). 26: e748-e754. PMID 31896945 DOI: 10.3747/co.26.4861 |
0.01 |
|
| 2019 |
Bender U, Rho YS, Barrera I, Aghajanyan S, Acoba J, Kavan P. Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions. Current Oncology (Toronto, Ont.). 26: S43-S52. PMID 31819709 DOI: 10.3747/co.26.5605 |
0.01 |
|
| 2019 |
Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902107. PMID 31725351 DOI: 10.1200/JCO.19.02107 |
0.01 |
|
| 2019 |
Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, et al. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. Jama Oncology. PMID 31486832 DOI: 10.1001/jamaoncol.2019.2792 |
0.01 |
|
| 2019 |
Riechelmann RP, Srimuninnimit V, Bordonaro R, Kavan P, Di Bartolomeo M, Maiello E, Cicin I, García-Alfonso P, Chau I, Fedyanin MY, Martos CF, Ter-Ovanesov M, Peeters M, Ko YJ, Yalcin S, et al. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). Clinical Colorectal Cancer. PMID 31221542 DOI: 10.1016/j.clcc.2019.05.003 |
0.01 |
|
| 2019 |
Ko YJ, Abdelsalam M, Kavan P, Lim H, Tang PA, Vincent M, Wong R, Kish M, Gill S. What is a clinically meaningful survival benefit in refractory metastatic colorectal cancer? Current Oncology (Toronto, Ont.). 26: e255-e259. PMID 31043834 DOI: 10.3747/co.26.4753 |
0.01 |
|
| 2018 |
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, ... ... Kavan P, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. The New England Journal of Medicine. 379: 2395-2406. PMID 30575490 DOI: 10.1056/NEJMoa1809775 |
0.01 |
|
| 2018 |
Aubin S, Rosberger Z, Hafez N, Noory MR, Perez S, Lehmann S, Batist G, Kavan P. Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young Adults with Cancer. Journal of Adolescent and Young Adult Oncology. PMID 30484730 DOI: 10.1089/Jayao.2017.0101 |
0.01 |
|
| 2018 |
Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, Shivakumar S, Tagalakis V, Wu C, Lee AYY. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Current Oncology (Toronto, Ont.). 25: 329-337. PMID 30464682 DOI: 10.3747/co.25.4266 |
0.01 |
|
| 2018 |
Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, et al. Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial. Clinical Colorectal Cancer. PMID 30415988 DOI: 10.1016/j.clcc.2018.09.011 |
0.01 |
|
| 2018 |
McGee SF, AlGhareeb W, Ahmad CH, Armstrong D, Babak S, Berry S, Biagi J, Booth C, Bossé D, Champion P, Colwell B, Finn N, Goel R, Gray S, Green J, ... ... Kavan P, et al. Eastern Canadian Colorectal Cancer Consensus Conference 2017. Current Oncology (Toronto, Ont.). 25: 262-274. PMID 30111967 DOI: 10.3747/Co.25.4083 |
0.01 |
|
| 2017 |
Ibrahim M, Muanza T, Smirnow N, Sateren W, Fournier B, Kavan P, Palumbo M, Dalfen R, Dalzell MA. A Pilot Randomized Controlled Trial on the Effects of a Progressive Exercise Program on the Range of Motion and Upper Extremity Grip Strength in Young Adults With Breast Cancer. Clinical Breast Cancer. PMID 28733130 DOI: 10.1016/j.clbc.2017.06.007 |
0.01 |
|
| 2017 |
Ibrahim M, Muanza T, Smirnow N, Sateren W, Fournier B, Kavan P, Palumbo M, Dalfen R, Dalzell MA. Time course of upper limb function and return-to-work post-radiotherapy in young adults with breast cancer: a pilot randomized control trial on effects of targeted exercise program. Journal of Cancer Survivorship : Research and Practice. PMID 28470507 DOI: 10.1007/s11764-017-0617-0 |
0.01 |
|
| 2017 |
Rho YS, Gilabert M, Polom K, Aladashvili A, Kopeckova K, Megdanova V, Coleman N, Greally M, Marrelli D, Roviello F, McDermott R, Petrova V, Mihaylova Z, Bortlicek Z, Prausova J, ... ... Kavan P, et al. Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study. Clinical Colorectal Cancer. PMID 28462853 DOI: 10.1016/J.Clcc.2017.03.008 |
0.01 |
|
| 2017 |
Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, Kavan P, Raoul JL. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine. 96: e6544. PMID 28422841 DOI: 10.1097/Md.0000000000006544 |
0.01 |
|
| 2016 |
Gilabert M, Rho YS, Kavan P. Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas. Oncology. PMID 27838688 DOI: 10.1159/000452279 |
0.01 |
|
| 2016 |
Mamo A, Baig A, Azam M, Rho YS, Sahebjam S, Muanza T, Owen S, Petrecca K, Guiot MC, Al-Shami J, Sharma R, Kavan P. Progression pattern and adverse events with bevacizumab in glioblastoma. Current Oncology (Toronto, Ont.). 23: e468-e471. PMID 27803607 DOI: 10.3747/co.23.3108 |
0.01 |
|
| 2016 |
Mamo A, Easaw J, Ibnshamsah F, Baig A, Rho YS, Kavan T, Batist G, Kavan P. Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting. Current Oncology (Toronto, Ont.). 23: 171-7. PMID 27330345 DOI: 10.3747/Co.23.3059 |
0.01 |
|
| 2016 |
Di Valentin T, Asmis T, Asselah J, Aubin F, Aucoin N, Berry S, Biagi J, Booth CM, Burkes R, Coburn N, Colwell B, Cripps C, Dawson LA, Dorreen M, Frechette D, ... ... Kavan P, et al. Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers. Current Oncology (Toronto, Ont.). 23: 52-5. PMID 26966404 DOI: 10.3747/Co.23.2897 |
0.01 |
|
| 2015 |
Rho YS, Barrera I, Metrakos P, Kavan P. Complete Resolution of Metastatic Gallbladder Cancer after Standard Gemcitabine-Cisplatin Combination Therapy. CurēUs. 7: e415. PMID 26848408 DOI: 10.7759/cureus.415 |
0.01 |
|
| 2015 |
Xu Y, Stavrides-Eid M, Baig A, Cardoso M, Rho YS, Shams WM, Mamo A, Kavan P. Quantifying treatment delays in adolescents and young adults with cancer at McGill University. Current Oncology (Toronto, Ont.). 22: e470-7. PMID 26715885 DOI: 10.3747/co.22.2724 |
0.01 |
|
| 2015 |
McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, Batist G, Kavan P. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. Clinical Colorectal Cancer. PMID 26553578 DOI: 10.1016/J.Clcc.2015.10.003 |
0.01 |
|
| 2015 |
Pettigrew M, Kavan P, Surprenant L, Lim HJ. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada. Journal of Medical Economics. 1-36. PMID 26442575 DOI: 10.3111/13696998.2015.1105230 |
0.01 |
|
| 2015 |
Alshami J, Guiot MC, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon DA, Muanza T. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget. 6: 34030-7. PMID 26423602 DOI: 10.18632/oncotarget.5297 |
0.01 |
|
| 2015 |
Hu H, Li X, Nguyen AD, Kavan P. A Critical Evaluation of Waste Incineration Plants in Wuhan (China) Based on Site Selection, Environmental Influence, Public Health and Public Participation. International Journal of Environmental Research and Public Health. 12: 7593-614. PMID 26184242 DOI: 10.3390/ijerph120707593 |
0.01 |
|
| Hide low-probability matches. |